Items where authors include "Low, E"

Export as [feed] Atom [feed] RSS
Number of items: 7.

Article

Niemi, MEK, Karjalainen, J, Liao, RG et al. (3763 more authors) (2021) Mapping the human genetic architecture of COVID-19. Nature, 600 (7889). pp. 472-477. ISSN 0028-0836

Drayson, MT, Bowcock, S, Planche, T et al. (23 more authors) (2019) Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial. The Lancet Oncology, 20 (12). pp. 1760-1772. ISSN 1470-2045

Drayson, MT, Bowcock, S, Planche, T et al. (13 more authors) (2019) Prophylactic levofloxacin to prevent infections in newly diagnosed symptomatic myeloma: the TEAMM RCT. Health Technology Assessment, 23 (62). pp. 1-94. ISSN 1366-5278

Popat, R, Brown, SR, Flanagan, L et al. (10 more authors) (2019) Extended follow‐up and the feasibility of Panobinostat maintenance for patients with Relapsed Multiple Myeloma treated with Bortezomib, Thalidomide, Dexamethasone plus Panobinostat (MUK six open label, multi‐centre phase I/II Clinical Trial). British Journal of Haematology, 185 (3). pp. 573-578. ISSN 0007-1048

Popat, R, Brown, SR, Flanagan, L et al. (9 more authors) (2016) Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial. The Lancet Haematology, 3 (12). e572-e580. ISSN 2352-3026

Brown, S, Hinsley, S orcid.org/0000-0001-6903-4688, Ballesteros, M et al. (11 more authors) (2016) The MUK five protocol: a phase II randomised, controlled, parallel group, multi-centre trial of carfilzomib, cyclophosphamide and dexamethasone (CCD) vs. cyclophosphamide, bortezomib (Velcade) and dexamethasone (CVD) for first relapse and primary refractory multiple myeloma. BMC hematology, 16. p. 14. ISSN 2052-1839

Proceedings Paper

Yong, KL, Brown, S, Hinsley, S orcid.org/0000-0001-6903-4688 et al. (8 more authors) (2015) Carfilzomib, Cyclophosphamide and Dexamethasone Is Well Tolerated in Patients with Relapsed/Refractory Multiple Myeloma Who Have Received One Prior Regimen. In: Blood. 57th ASH Annual Meeting and Exposition, 05-08 Dec 2015, Orlando, FL, USA. American Society of Hematology .

This list was generated on Sun Mar 24 05:56:42 2024 GMT.